Multivariable clinical-genetic model for predicting dyskinesia in early-onset Parkinson’s disease  

作　　者：Yong-Ping Chen Ru-Wei Ou Xiao-Jing Gu Ling-Yu Zhang Bei Cao Yan-Bing Hou Kun-Cheng Liu Jun-Yu Lin Qian-Qian Wei Bi Zhao Ying Wu Hui-Fang Shang 

机构地区：[1]Department of Neurology,Laboratory of Neurodegenerative Disorders,Rare Disease Center,West China Hospital,Sichuan University,Chengdu 610041,China

出　　处：《Translational Neurodegeneration》2021年第3期343-345,共3页转化神经变性病（英文）

基　　金：This study was supported by the National Key Research and Development Program of China(2018YFC1312001 and 2016YFC0901504);the National Natural Science Foundation of China(81971188);the 1.3.5 project for Disciplines of Excellence,West China Hospital,Sichuan University(ZYJC18038,ZYJC18003 and 2019HXFH046).

摘　　要：Main text The levodopa-induced dyskinesias(LIDs)in Parkinson’disease(PD)patients during levodopa treatment can lead to significant disability.Accumulative evidence has suggested that the younger the age of onset,the more likely the development of LIDs[1].Till now,most of the studies on clinical or genetic risk factors for LIDs were cross-sectional[2],or included limited sample size[3],or mainly included late-onset PD patients[4].Here,we investigated the incidence of LIDs in the early stage of early-onset PD(EOPD),including the first 5 years of duration and the first 5 years of dopamine replacement therapy(DRT),and established and validated clinicalgenetic models for LID prediction.Detailed methods are provided in Supplementary File 1.

关 键 词：CLINICAL DOPAMINE YOUNGER 

分 类 号：R742.5[医药卫生—神经病学与精神病学]